Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences (Nasdaq: IDYA) announced the effectiveness of its strategic partnership with GlaxoSmithKline (GSK) after receiving clearance under the Hart-Scott-Rodino Act. This collaboration includes an upfront cash payment of $100 million and focuses on Synthetic Lethality programs. Additionally, IDEAYA closed a direct private placement equity financing with Glaxo Group, raising approximately $20 million by selling 1,333,333 shares at $15.00 each. IDEAYA expects sufficient funds to support operations into 2024.
IDEAYA Biosciences (Nasdaq: IDYA) announced the achievement of clinical protocol criteria for cohort expansion in the Phase 2 basket trial of IDE196 targeting melanoma patients with GNAQ or GNA11 mutations. The trial has enrolled 5 patients, including 1 with a confirmed partial response. If further responses are observed, an additional 15 patients may join, bringing total enrollment to 24. IDEAYA anticipates interim data for IDE196 monotherapy in early 2021, while the impact of Covid-19 on trials is being monitored.
IDEAYA Biosciences (Nasdaq: IDYA) announced its participation in two investor conferences in August 2020. CEO Yujiro S. Hata will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 11 at 1:00 pm EST. He will also participate in the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 8:00 am EST, discussing his recent report on synthetic lethality in cancer. Live webcasts will be available on IDEAYA's website, with replays accessible for 30 days afterward.
IDEAYA Biosciences (NASDAQ:IDYA) announced the First-Patient-In in a Phase 1 study evaluating the combination of IDE196 and binimetinib for metastatic uveal melanoma (MUM). This collaboration with Pfizer aims to enhance IDE196's clinical activity through rational combinations. The company is also focusing on IDE196's monotherapy in non-MUM settings. Preliminary data from the MEK combination study is expected in late 2021 to early 2022, potentially leading to a registrational path for MUM and future partnerships.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) appointed Garret Hampton, Ph.D. to its Board of Directors on June 30, 2020. Dr. Hampton, with over 25 years of experience, is currently President of Clinical Sequencing and Oncology at Thermo Fisher Scientific and has held significant roles at Illumina and Genentech. His expertise in biomarker discovery is seen as crucial for advancing IDEAYA's Synthetic Lethality programs, notably targeting MTAP-deletion in solid tumors. The company aims to enhance global access to oncology diagnostics as it progresses its targeted therapies.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has priced an underwritten public offering of 6,666,667 shares of its common stock at $15.00 per share, potentially raising $100 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 1,000,000 shares. Proceeds will support the development of IDE397, IDE196, and other pipeline candidates, as well as general corporate purposes. The offering is scheduled to close around June 22, 2020.
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) announced a proposed public offering of up to $60 million in common stock, with an additional $9 million option for underwriters. Proceeds will fund development of drug candidates including IDE397 and IDE196, along with biomarker research and working capital. The offering is subject to market conditions and will utilize a shelf registration statement previously filed with the SEC. J.P. Morgan, Citigroup, and Jefferies are acting as joint book-running managers.
IDYA has partnered with GlaxoSmithKline (GSK) to advance Synthetic Lethality programs, including MAT2A and Pol Theta. These programs, projected to enter clinical trials in the next three years, utilize innovative approaches to target cancer-specific vulnerabilities. IDEAYA will manage the MAT2A program's early development, covering initial costs, while sharing profits with GSK. The collaboration aims to enhance precision medicine in oncology, focusing on significant solid tumors. Regulatory clearance is required to finalize the partnership.